Article Details
Retrieved on: 2024-04-26 17:13:42
Tags for this article:
Click the tags to see associated articles and topics
Summary
Generative Adversarial Networks (GANs) were used by Insilico Medicine to design ISM3412, an MAT2A inhibitor for treating MTAP-deleted cancers, now approved for Phase I trials by the FDA. This aligns with the tags 'Synthetic lethality,' 'Cancer treatment,' and 'MTAP.'
Article found on: www.news-medical.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here